FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis
正文 · 中文译文
FDA加速批准Darzalex Faspro用于新诊断轻链淀粉样变性 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2021年1月15日,美国食品药品监督管理局(FDA)加速批准达雷妥尤单抗联合透明质酸酶(Darzalex Faspro,杨森生物技术公司)联合硼替佐米、环磷酰胺和地塞米松用于新诊断轻链(AL)淀粉样变性。 疗效在ANDROMEDA(NCT03201965)中评估,该研究是一项开放标签、随机、活性对照试验,纳入388例新诊断AL淀粉样变性患者,患者具有可测量疾病且根据共识标准至少有一个受累器官。患者随机接受硼替佐米、环磷酰胺和地塞米松(VCd组)或联合Darzalex Faspro(D-VCd组)。 基于既定共识缓解标准、由独立审查委员会评估的血液学完全缓解(HemCR)率在D-VCd组为42.1%,在VCd组为13.5%(比值比=4.8;95% CI:2.9,8.1;p<0.0001)。 处方信息包含“警告与注意事项”,指出接受 Darzalex Faspro 联合硼替佐米、环磷酰胺和地塞米松治疗的轻链(AL)淀粉样变性患者中发生了严重或致命性心脏不良事件。Darzalex Faspro 未获批适应证,且不推荐用于在对照临床试验之外治疗纽约心脏协会(NYHA)IIIB 级或 IV 级心脏病或 Mayo IIIB 期的轻链(AL)淀粉样变性患者。 在接受 D-VCd 方案的轻链(AL)淀粉样变性患者中,最常见的不良反应(≥20%)为上呼吸道感染、腹泻、外周水肿、便秘、外周感觉神经病、疲乏、恶心、失眠、呼吸困难和咳嗽。 Darzalex Faspro 的推荐剂量为(1,800 mg 达雷妥尤单抗和 30,000 单位透明质酸酶),按照推荐方案联合 VCd,经腹部皮下给药,给药时间约为 3 至 5 分钟。 查看 Darzalex Faspro 的完整处方信息。 本审评在 Project Orbis 框架下开展,该项目是美国食品药品监督管理局(FDA)肿瘤卓越中心的一项倡议。Project Orbis 为国际合作伙伴之间肿瘤药物的同步提交和审评提供了框架。本次审评中,FDA 与澳大利亚治疗用品管理局(TGA)、巴西卫生监管局(ANVISA)、加拿大卫生部以及瑞士 Swissmedic 合作。ANVISA 于 2020 年 11 月 30 日批准了该申请。其他监管机构的申请审评仍在进行中。 本综述采用了实时肿瘤学审评(RTOR)试点项目,该项目在完整临床应用申报提交之前简化了数据提交过程,并采用了评估辅助工具,这是申请人自愿提交以促进FDA评估的材料。FDA比FDA目标日期提前7周批准了该申请。 本申请基于缓解率获得了加速批准。该适应症的继续批准可能取决于确证性试验中对临床获益的验证和描述。 医疗专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需关于研究性肿瘤产品单患者IND的协助,医疗专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 关于COVID-19大流行的信息,请参阅以下资源: FDA:2019冠状病毒病(COVID-19) NCI:冠状病毒:癌症患者应了解的内容 CDC:冠状病毒(COVID-19) 在Twitter上关注肿瘤学卓越中心 @FDAOncology。 内容截至日期: 01/15/2021 受监管产品 药物 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On January 15, 2021, the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis. Efficacy was evaluated in ANDROMEDA (NCT03201965), an open-label, randomized, active-controlled trial in 388 patients with newly diagnosed AL amyloidosis with measurable disease and at least one affected organ according to consensus criteria. Patients were randomized to receive bortezomib, cyclophosphamide, and dexamethasone (VCd arm) or with Darzalex Faspro (D-VCd arm). The hematologic complete response (HemCR) rate based on established consensus response criteria as evaluated by an independent review committee was 42.1% for the D-VCd arm and 13.5% for the VCd arm (odds ratio=4.8; 95% CI: 2.9, 8.1; p<0.0001). The prescribing information includes a Warnings and Precautions that serious or fatal cardiac adverse reactions occurred in patients with light chain (AL) amyloidosis who received Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone. Darzalex Faspro is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials. The most common adverse reactions (≥20%) in patients with light chain (AL) amyloidosis who received the D-VCd regimen are upper respiratory tract infection, diarrhea, peripheral edema, constipation peripheral sensory neuropathy, fatigue, nausea, insomnia, dyspnea and cough. The recommended Darzalex Faspro dose is (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously into the abdomen over approximately 3 to 5 minutes according to recommended schedule in combination with VCd. View full prescribing information for Darzalex Faspro. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, and Switzerland’s Swissmedic. ANVISA approved this application on November 30, 2020. The application reviews are ongoing at the other regulatory agencies. This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 7 weeks ahead of the FDA goal date. This application was granted accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncology. Content current as of: 01/15/2021 Regulated Product(s) Drugs Oncology
摘要 待译
On January 15, 2021, the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis.